S Elsamany1, A Alzahrani2, W N Abozeed3, A Rasmy4, M U Farooq5, M A Elbiomy6, E Rawah7, K Alsaleh8, N M Abdel-Aziz9. 1. Oncology, King Abdullah Medical City, Makkah, Saudi Arabia; Oncology, Oncology centre, Mansoura University, Mansoura, Egypt. Electronic address: shereefmohamad@yahoo.com. 2. Oncology, King Abdullah Medical City, Makkah, Saudi Arabia. 3. Medical Oncology, King Khaled Hospital, King Saud University, Riyadh, Saudi Arabia; Clinical Oncology, Mansoura University Hospital, Mansoura, Egypt. 4. Oncology, King Fahd Specialist Hospital, Dammam, Saudi Arabia; Oncology, Zagazig University Hospital, Zagazig, Egypt. 5. Research, King Abdullah Medical City, Makkah, Saudi Arabia. 6. Oncology, Oncology centre, Mansoura University, Mansoura, Egypt. 7. Radiology, King Abdullah Medical City, Makkah, Saudi Arabia. 8. Medical Oncology, King Khaled Hospital, King Saud University, Riyadh, Saudi Arabia. 9. Medical Oncology, King Khaled Hospital, King Saud University, Riyadh, Saudi Arabia; Medical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt.
Abstract
BACKGROUND: This study aims to evaluate the relation between mammographic breast density (BD) and pathological response to neoadjuvant chemotherapy. METHODS: In this retrospective study, 241 breast cancer patients who received neoadjuvant chemotherapy were included. BD was assessed in mammograms already performed at diagnosis. Pathological complete response (pCR) and pathological stage were correlated with BD, tumour phenotype and other clinico-pathological factors. RESULTS: Patients with low BD had better pCR compared to those with high density (30.5% vs 19.5% respectively, OR = 1.8, 95% CI = 0.98-3.3, p = 0.056) which was more pronounced after adjustment with body mass index (BMI) (OR = 2.4, 95% CI = 1.2-4.8, p = 0.011). HER2-positive disease (32.5% vs. 18.4%, OR = 2.2, 95% = 1.2-4.0, p = 0.01), lower BMI (OR = 1.1, 95% CI = 1.03-1.15, p = 0.004) and lower clinical stage (p = 0.002) were significant predictors of pCR in univariate analysis. In multivariate analysis, low BD (OR = 2.7, 95% CI = 1.3-5.5, p = 0.006) and lower BMI (OR = 1.1, 95% CI = 1.03-1.17, p = 0.003) were independent predictors of better pCR, while early clinical stage (I, II) was of borderline significance (OR = 2.6, 95% CI = 0.99-6.7, p = 0.052). High BD (OR = 1.8, 95% CI = 1.1-3.2, p = 0.03), advanced clinical stage (III) (OR = 1.5, 95% CI = 1.03-2.1, p = 0.03) and higher BMI (OR = 1.06, 95% CI = 1.02-1.11, p = 0.006) were significant predictors of advanced pathological stage. CONCLUSION: Low mammographic BD, low BMI and early clinical stage were associated with improved pCR rate and lower pathological stage after neoadjuvant chemotherapy. BD had more pronounced association with response to chemotherapy after adjustment with BMI.
BACKGROUND: This study aims to evaluate the relation between mammographic breast density (BD) and pathological response to neoadjuvant chemotherapy. METHODS: In this retrospective study, 241 breast cancerpatients who received neoadjuvant chemotherapy were included. BD was assessed in mammograms already performed at diagnosis. Pathological complete response (pCR) and pathological stage were correlated with BD, tumour phenotype and other clinico-pathological factors. RESULTS:Patients with low BD had better pCR compared to those with high density (30.5% vs 19.5% respectively, OR = 1.8, 95% CI = 0.98-3.3, p = 0.056) which was more pronounced after adjustment with body mass index (BMI) (OR = 2.4, 95% CI = 1.2-4.8, p = 0.011). HER2-positive disease (32.5% vs. 18.4%, OR = 2.2, 95% = 1.2-4.0, p = 0.01), lower BMI (OR = 1.1, 95% CI = 1.03-1.15, p = 0.004) and lower clinical stage (p = 0.002) were significant predictors of pCR in univariate analysis. In multivariate analysis, low BD (OR = 2.7, 95% CI = 1.3-5.5, p = 0.006) and lower BMI (OR = 1.1, 95% CI = 1.03-1.17, p = 0.003) were independent predictors of better pCR, while early clinical stage (I, II) was of borderline significance (OR = 2.6, 95% CI = 0.99-6.7, p = 0.052). High BD (OR = 1.8, 95% CI = 1.1-3.2, p = 0.03), advanced clinical stage (III) (OR = 1.5, 95% CI = 1.03-2.1, p = 0.03) and higher BMI (OR = 1.06, 95% CI = 1.02-1.11, p = 0.006) were significant predictors of advanced pathological stage. CONCLUSION: Low mammographic BD, low BMI and early clinical stage were associated with improved pCR rate and lower pathological stage after neoadjuvant chemotherapy. BD had more pronounced association with response to chemotherapy after adjustment with BMI.
Authors: Michael S Shawky; Cecilia W Huo; Kara Britt; Erik W Thompson; Michael A Henderson; Andrew Redfern Journal: Breast Cancer Res Treat Date: 2019-06-08 Impact factor: 4.872
Authors: Haiyun Wang; Shijia Zhang; Douglas Yee; Saonli Basu; Heather Beckwith; David Potter; Anne Blaes Journal: Breast Cancer Date: 2021-01-02 Impact factor: 4.239
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872
Authors: Ida Skarping; Daniel Förnvik; Uffe Heide-Jørgensen; Hanna Sartor; Per Hall; Sophia Zackrisson; Signe Borgquist Journal: Breast Date: 2020-06-04 Impact factor: 4.380
Authors: Ida Skarping; Daniel Förnvik; Uffe Heide-Jørgensen; Hanna Sartor; Per Hall; Sophia Zackrisson; Signe Borgquist Journal: Cancer Causes Control Date: 2020-12-30 Impact factor: 2.506
Authors: Gina Reye; Xuan Huang; Larisa M Haupt; Ryan J Murphy; Jason J Northey; Erik W Thompson; Konstantin I Momot; Honor J Hugo Journal: J Mammary Gland Biol Neoplasia Date: 2021-08-27 Impact factor: 2.673
Authors: Xuan Huang; Gina Reye; Konstantin I Momot; Tony Blick; Thomas Lloyd; Wayne D Tilley; Theresa E Hickey; Cameron E Snell; Rachel K Okolicsanyi; Larisa M Haupt; Vito Ferro; Erik W Thompson; Honor J Hugo Journal: Front Cell Dev Biol Date: 2020-07-14
Authors: Signe Borgquist; Lisa Rydén; Ida Skarping; Daniel Förnvik; Sophia Zackrisson Journal: Breast Cancer Res Treat Date: 2021-06-12 Impact factor: 4.872